BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/10/2014 5:06:00 PM | Browse: 607 | Download: 235
Publication Name World Journal of Hepatology
Manuscript ID 3671
Country/Territory Italy
Received
2013-05-14 08:20
Peer-Review Started
2013-05-14 15:03
To Make the First Decision
2013-05-23 17:19
Return for Revision
2013-05-24 10:01
Revised
Second Decision
2013-09-18 10:54
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-09-18 11:29
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
2013-09-24 21:01
Typeset the Manuscript
2013-10-23 18:52
Publish the Manuscript Online
2013-10-25 08:47
ISSN 1948-5182 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Review
Article Title Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis
Manuscript Source Invited Manuscript
All Author List Gianni Testino and Paolo Borro
Funding Agency and Grant Number
Corresponding Author Gianni Testino, MD, Department of Internal e Specialistic Medicine, Centro Alcologico Regionale–Regione Liguria, UO Alcologia e Patologie Correlate, Padiglione 10 (piano Terra), Piazzale R. Benzi 10, 16132 Genova, Italy. gianni.testino@hsanmartino.it
Key Words Chemoprevention; Cirrhosis; Hepatitis C virus; Hepatocellular carcinoma
Core Tip Interferon (IFN) therapy has been reported to decrease the risk of hepatocellular carcinoma (HCC) and improve survival. The use of IFN in patients with hepatitis C virus (HCV) compensated cirrhosis reduces the negative clinical evolution independently of the type of the laboratoristic and virological response. In our experience, IFN therapy in HCV compensated cirrhosis is barely useful in the prevention of HCC, as cirrhosis itself represents a risk of cancer. It would probably be interesting to evaluate the efficacy of weekly low-dose pegylated (PEG)-IFN therapy in patients with HCV cirrhosis and to assess potential benefits of long-term PEG-IFN plus Ribavirin treatment.
Publish Date 2013-10-25 08:47
Citation Testino G, Borro P. Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis. World J Hepatol 2013; 5(10): 521-527
Url http://www.wjgnet.com/1948-5182/full/v5/i10/521.htm
DOI http://dx.doi.org/10.4254/wjh.v5.i10.521
Full Article (PDF) WJH-5-521.pdf
Manuscript File 3671-Review.edited.doc
Peer-review Report 3671-Peer reviews.pdf
Scientific Editor Work List 3671-Scientific editor work list.doc